We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

80 hedge funds and large institutions have $757M invested in ArriVent BioPharma in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 11 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

209% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 11

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

24% more capital invested

Capital invested by funds: $612M → $757M (+$145M)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

18% more funds holding

Funds holding: 68 → 80 (+12)

7.33% more ownership

Funds ownership: 77.13% → 84.47% (+7.3%)

Holders
80
Holders Change
+12
Holders Change %
+17.65%
% of All Funds
1.05%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.08%
New
24
Increased
34
Reduced
11
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
+$11.5M
2
State Street
State Street
Massachusetts
+$9.68M
3
BlackRock
BlackRock
New York
+$5.85M
4
HLAM
Hidden Lake Asset Management
New York
+$5.3M
5
Goldman Sachs
Goldman Sachs
New York
+$3.86M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$9.75M
2
Millennium Management
Millennium Management
New York
-$4.71M
3
Marshall Wace
Marshall Wace
United Kingdom
-$2M
4
GCM
Ghisallo Capital Management
Massachusetts
-$1.18M
5
SVCM
Saturn V Capital Management
Texas
-$1.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
HA
1
HHLR Advisors
Cayman Islands
$119M – – –
O
2
OrbiMed
New York
$80.6M – – –
SCM
3
Suvretta Capital Management
New York
$59.8M +$11.5M +400,838 +22%
BlackRock
4
BlackRock
New York
$56.9M +$5.85M +203,673 +11%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$56M -$536K -18,658 -0.9%
OCA
6
Octagon Capital Advisors
New York
$54.9M +$2.38M +83,000 +4%
SI
7
Sofinnova Investments
California
$45.2M – – –
IAM
8
Infinitum Asset Management
Florida
$43.8M +$47.2M +1,643,923 New
NHAS
9
Novo Holdings A/S
Denmark
$40.5M +$440K +15,312 +1%
GCGM
10
General Catalyst Group Management
Massachusetts
$39.8M – – –
Vanguard Group
11
Vanguard Group
Pennsylvania
$37.8M +$2.06M +71,741 +5%
State Street
12
State Street
Massachusetts
$21.7M +$9.68M +337,282 +71%
HH
13
HSG Holding
Hong Kong
$16.8M – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$15.9M -$28.2K -983 -0.2%
CAM
15
Cormorant Asset Management
Massachusetts
$15.6M – – –
Northern Trust
16
Northern Trust
Illinois
$6.42M +$301K +10,498 +5%
Goldman Sachs
17
Goldman Sachs
New York
$5.52M +$3.86M +134,301 +184%
Charles Schwab
18
Charles Schwab
California
$5.5M +$115K +4,011 +2%
HLAM
19
Hidden Lake Asset Management
New York
$4.92M +$5.3M +184,605 New
Morgan Stanley
20
Morgan Stanley
New York
$3.96M -$550K -19,150 -11%
WP
21
Woodline Partners
California
$3.88M +$714K +24,853 +21%
UBS Group
22
UBS Group
Switzerland
$1.94M +$1.55M +54,057 +290%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.81M -$9.13K -318 -0.5%
Barclays
24
Barclays
United Kingdom
$1.43M +$344K +11,977 +29%
Millennium Management
25
Millennium Management
New York
$1.4M -$4.71M -164,085 -76%
1
2 3 4

AVBP Hedge Fund Activity: Q4 2024 in Review

80 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q4 2024, worth a combined $757M — up 24% from $612M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new AVBP positions and 11 closed out — a net gain of 13 holders — while 34 added to existing stakes and 11 trimmed.

The largest buyer was Suvretta Capital Management, adding an estimated $11.5M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $9.75M sold.

  • 80 institutional investors held ArriVent BioPharma (AVBP) as of Q4 2024, up from 68 in Q3 2024.
  • Funds reported $757M of ArriVent BioPharma stock for Q4 2024, up 24% quarter-over-quarter.
  • 24 funds opened new ArriVent BioPharma positions in Q4 2024 and 11 closed out, a net change of +13 holders.
  • The largest ArriVent BioPharma buyer in Q4 2024 was Suvretta Capital Management, an estimated $11.5M added.
  • The largest ArriVent BioPharma seller in Q4 2024 was Perceptive Advisors, an estimated $9.75M sold.

Based on aggregated 13F filings for Q4 2024.